Närhälsan Norrmalm Health Centre, Ekängsvägen 15, 541 41 Skövde, Sweden; Department of Public Health and Community Medicine/Primary Health Care, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden.
Närhälsan R&D Centre Skaraborg Primary Care, Långgatan 18, 541 30 Skövde, Sweden.
Diabetes Res Clin Pract. 2018 Apr;138:81-89. doi: 10.1016/j.diabres.2018.01.038. Epub 2018 Feb 5.
Our aim was to assess causes of death and temporal changes in excess mortality among patients with new-onset type 2 diabetes in Skaraborg, Sweden.
Patients from the Skaraborg Diabetes Register with prospectively registered new-onset type 2 diabetes 1991-2004 were included. Five individual controls matched for sex, age, geographical area and calendar year of study entry were selected using population records. Causes of deaths until 31 December 2014 were retrieved from the Cause of Death Register. Adjusted excess mortality among patients and temporal changes of excess mortality were calculated using Poisson models. Cumulative incidences of cause-specific mortality were calculated by competing risk regression.
During 24 years of follow-up 4364 deaths occurred among 7461 patients in 90,529 person-years (48.2/1000 person-years, 95% CI 46.8-49.7), and 18,541 deaths in 479,428 person-years among 37,271 controls (38.7/1000 person-years, 38.1-39.2). The overall adjusted mortality hazard ratio was 1.47 (p < .0001) among patients diagnosed at study start 1991 and decreased by 2% (p < .0001) per increase in calendar year of diagnosis until 2004. Excess mortality was mainly attributed to endocrine and cardiovascular cause of death with crude subdistributional hazard ratios of 5.06 (p < .001) and 1.22 (p < .001).
Excess mortality for patients with new-onset type 2 diabetes was mainly attributed to deaths related to diabetes and the cardiovascular system, and decreased with increasing year of diagnosis 1991-2004. Possible explanations could be temporal trends of earlier diagnosis due to lowered diagnostic thresholds and intensified diagnostic activities, as well as improved treatment.
本研究旨在评估瑞典斯科讷省新诊断 2 型糖尿病患者的死亡原因和超额死亡率的时间变化。
纳入了 1991-2004 年斯科讷糖尿病登记处中前瞻性登记的新诊断 2 型糖尿病患者。使用人群记录,为每位患者选择了 5 名性别、年龄、地理区域和研究入组年份相匹配的个体对照。通过死因登记处获取截至 2014 年 12 月 31 日的死因。使用泊松模型计算患者的超额死亡率和超额死亡率的时间变化,并使用竞争风险回归计算特定原因死亡率的累积发生率。
在 24 年的随访期间,7461 例患者(90529 人年)中发生了 4364 例死亡(48.2/1000 人年,95%CI 46.8-49.7),37271 例对照(479428 人年)中发生了 18541 例死亡(38.7/1000 人年,38.1-39.2)。1991 年研究开始时诊断的患者总体调整死亡率危险比为 1.47(p<0.0001),诊断年份每增加一年,超额死亡率降低 2%(p<0.0001)。超额死亡率主要归因于内分泌和心血管死亡原因,粗亚分布危险比分别为 5.06(p<0.001)和 1.22(p<0.001)。
新诊断 2 型糖尿病患者的超额死亡率主要归因于糖尿病和心血管系统相关死亡,且随着 1991-2004 年诊断年份的增加而降低。可能的解释包括由于诊断阈值降低和诊断活动加强,以及治疗改善,导致更早诊断的时间趋势。